Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesImmunocore Holdings Ltd

Immunocore Holdings Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
32.01 USD 0.28 ( 0.88%)
Last update at 2026-11-10T17:57:00Z
VOLUME
289579
Market Cap
1636.37M

Momentum Score

…

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
31.52
Low
32.09
High
52 Week Price Range
27.55
Low
40.71
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Immunocore Holdings Ltd develops T‑cell receptor–based bispecific therapies via its ImmTAC platform to redirect T cells against intracellular cancer and infectious disease targets. Long-term growth drivers include commercialization of existing products, pipeline expansion and partnerships, and the company may appeal to investors because the platform has achieved regulatory validation and targets antigens that are difficult to address with conventional approaches.
Key risks are dependence on a single marketed therapy with a genetically limited addressable population (HLA‑A*02:01), high clinical and regulatory risk across the pipeline, competitive pressures, and the need for additional financing and commercial execution.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
31.73
Dividend Yield
-
Revenue TTM
430.78M
Revenue Per Share
8.50
Gross Profit TTM
141.59M
Debt / Equity
1.15
ROE
-4.47%
Net Debt
-31.02M
ROCE
-0.25%
Diluted EPS TTM
-0.36

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -14.21M -42.32M -48.19M -44.15M -140.93M
Net income -26.42M -40.81M -43.75M -41.22M -131.52M
Selling general administrative 165.41M 155.78M 154.85M 93.72M 88.40M
Gross profit 291.36M 242.44M 196.57M 143.28M 26.52M
Reconciled depreciation 3.27M 4.20M 5.31M 6.13M 7.01M
Ebit -2.04M -41.86M -44.11M -39.61M -135.16M
Ebitda 0.39M -38.50M -40.87M -36.45M -135.12M
Depreciation and amortization 2.43M 3.36M 3.24M 3.15M 0.05M
Operating income -33.74M -56.28M -47.20M -39.61M -135.16M
Other operating expenses 331.31M 304.31M 244.59M 183.34M 161.68M
Interest expense 12.17M 18.84M 4.08M 7.69M 5.81M
Tax provision 16.41M -1.85M 2.37M -2.92M -9.40M
Interest income 16.48M 25.62M 12.48M 3.15M 0.05M
Net interest income 4.31M 6.77M 4.48M -4.54M -5.77M
Income tax expense 12.21M -1.48M -4.43M -2.92M -9.40M
Total revenue 297.57M 247.98M 197.39M 143.74M 26.52M
Total operating expenses 325.09M 298.77M 243.77M 182.89M 161.68M
Cost of revenue 6.21M 5.54M 0.82M 0.45M -
Total other income expense net 19.53M 14.01M -0.98M -4.54M -5.77M
Net income from continuing ops -35.51M -51.09M -54.07M -41.22M -131.52M
Net income applicable to common shares - - - -41.22M -131.52M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1067.27M 1009.51M 597.00M 435.52M 301.77M
Intangible assets - - - 0.00M -
Other current assets 51.87M 20.95M 9.71M 0.06M 7.69M
Total liab 686.24M 648.79M 228.16M 156.76M 130.23M
Total stockholder equity 381.03M 360.72M 368.84M 278.76M 171.55M
Other current liab 219.74M 185.53M 114.32M 0.05M 0.04M
Common stock 0.14M 0.14M 0.14M 0.10M 0.09M
Capital stock 0.14M 0.14M 0.14M 0.10M 0.09M
Retained earnings -831.27M -795.76M -744.67M -261.25M -481.39M
Other liab - - - 5.92M 6.46M
Good will - - - 0.41M -
Other assets - - - 11.58M 7.51M
Cash 467.71M 455.73M 442.63M 332.54M 237.89M
Total current liabilities 246.70M 212.18M 139.02M 83.09M 61.18M
Current deferred revenue 0.58M 5.43M 5.51M 6.41M 24.45M
Net debt -31.02M -23.01M -358.59M -263.24M -174.05M
Short term debt 2.01M 1.55M 1.39M 1.55M 1.25M
Short long term debt total 436.69M 432.72M 84.03M 69.30M 63.84M
Other stockholder equity 1240.26M 1190.11M 1149.64M 205.16M 266.60M
Property plant equipment - - - 31.64M 31.54M
Total current assets 996.74M 929.86M 528.82M 391.88M 262.73M
Long term investments - - - 0.14M 0.17M
Net tangible assets - - - 278.35M 171.55M
Short term investments 396.44M 364.64M - - -
Net receivables 73.98M 83.10M 61.44M 58.40M 24.84M
Long term debt 393.12M 391.01M 48.01M 39.50M 37.23M
Inventory 6.74M 5.45M 4.50M 0.94M -7.69M
Accounts payable 24.36M 25.10M 17.80M 75.08M 35.44M
Accumulated other comprehensive income -28.08M -33.76M -36.26M 334.75M 386.26M
Non currrent assets other 20.28M 17.12M 14.47M 7.21M 4.77M
Non current assets total 70.53M 79.64M 68.18M 43.64M 39.05M
Capital lease obligations 43.56M 41.71M 36.02M 29.80M 26.61M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -12.00M -355.13M 4.79M 0.19M -0.37M
Change to liabilities - - - 18.63M 9.47M
Total cashflows from investing activities -12.16M -355.13M -4.29M 0.19M -0.37M
Net borrowings 0.00M 352.50M 0.00M -3.21M -3.16M
Total cash from financing activities 9.20M 343.88M 27.18M 138.23M 276.25M
Change to operating activities - - - 0.58M -21.28M
Net income -26.42M -51.09M -34.32M -41.22M -131.52M
Change in cash 8.89M 13.11M 31.78M 114.31M 146.03M
Begin period cash flow 338.23M 442.63M 318.50M 287.30M 175.12M
End period cash flow 347.11M 455.73M 350.27M 401.61M 321.15M
Total cash from operating activities -7.97M 26.06M 2.33M -31.27M -129.75M
Issuance of capital stock 0.00M 0.00M 0.00M 116.81M 226.53M
Depreciation 2.43M 4.20M 3.24M 6.13M 7.01M
Other cashflows from investing activities 4.18M 0.04M -0.93M 2.38M 0.56M
Dividends paid - - 0.00M 0.00M 0.00M
Change to inventory - - 29.04M - -
Change to account receivables -5.46M -12.35M -14.14M -32.09M -5.15M
Other cashflows from financing activities 3.17M -15.42M 27.18M 68.13M 52.88M
Change to netincome - - - 22.09M 45.36M
Capital expenditures 3.23M 5.17M 4.29M 2.20M 1.01M
Change in working capital -6.92M 45.13M 4.58M -12.88M -16.81M
Stock based compensation 37.70M 34.19M 25.69M 27.05M 35.86M
Other non cash items 11.94M -6.38M 3.14M -7.42M -14.89M
Free cash flow -11.20M 20.89M -1.97M -33.47M -130.76M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IMCR
Immunocore Holdings Ltd		 0.28
0.88%		 32.01 - 24.39 3.80 3.98 2.85 94.05
NVO
Novo Nordisk A/S		 -0.79
1.90%		 40.59 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.97
0.36%		 548.90 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -9.49
1.03%		 910.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Immunocore Holdings Ltd

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

92 Park Drive, Abingdon, United Kingdom, OX14 4RY

44 12 3543 8600

https://www.immunocore.com

524

Name Title Year Born
Dr. Bahija Jallal Ph.D. CEO & Director 1962
Mr. Brian R. Di Donato M.B.A. CFO & Head of Strategy 1967
Ms. Annelise Vuidepot Ph.D. CTO and Head of Pipeline & Platform Research NA
Clayton Robertson Head of Investor Relations NA
Ms. Lily Hepworth Gen. Counsel & Company Sec. NA
Ms. Amy Judge-Prein Chief Compliance Officer NA
Mr. Sébastien Desprez Head of Communications NA
Ms. Tina St. Leger Chief HR Officer 1969
Dr. David Berman M.D., Ph.D. Head of R&D 1971
Ms. Debra Nielsen Chief of Staff NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PET
CAD 22.84
+6.13%
QTWO
CAD 1.70
+5.59%
CHR
CAD 34.77
+5.59%
IFOS
CAD 1.77
+4.73%
GUD
CAD 12.02
+3.62%
MUX
CAD 18.68
-18.21%
URE
CAD 0.97
-14.16%
WELL
CAD 3.73
-12.24%
SGML
CAD 7.47
-10.54%
ISO
CAD 11.43
-10.14%

Equity Sectors*

  • Basic Materials

    -4.26%

  • Communication Services

    +0.36%

  • Consumer Cyclical

    -0.62%

  • Consumer Defensive

    -0.33%

  • Energy

    -0.09%

  • Financial Services

    -0.18%

  • Healthcare

    -1.69%

  • Industrials

    -1.10%

  • Real Estate

    -0.83%

  • Technology

    -0.67%

  • Utilities

    +0.31%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…